ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ODD ODDITY Tech Ltd.

Trading 12-23 12:21:53 EST

44.13

+0.37

+0.85%

High45.08	Low43.43	Vol105.35K
Open43.87	D1 Closing43.76	Amplitude3.77%
Mkt Cap2.52B	Tradable Cap738.45M	Total Shares57.12M
T/O4.65M	T/O Rate0.63%	Tradable Shares16.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":44.13,"timestamp":1734974505576,"preClose":43.76,"halted":0,"volume":105347,"delay":0,"floatShares":16733500,"shares":57120925,"eps":1.643643,"marketStatus":"Trading","change":0.37,"latestTime":"12-23 12:21:53 EST","open":43.87,"high":45.08,"low":43.43,"amount":4653597.535224,"amplitude":0.037706,"askPrice":44.2,"askSize":37,"bidPrice":43.96,"bidSize":96,"shortable":3,"etf":0,"ttmEps":1.643643,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":43.76,"preHourTrading":{"tag":"盘前","latestPrice":45.88,"preClose":43.76,"latestTime":"09:28 EST","volume":1836,"amount":83570.85522000001,"timestamp":1734964080008},"postHourTrading":{"tag":"盘后","latestPrice":43.76,"preClose":43.76,"latestTime":"18:35 EST","volume":10335,"amount":452235.46,"timestamp":1734737713506},"volumeRatio":0.502416,"impliedVol":0.5739,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/ODD/wiki","defaultTab":"wiki","newsList":[{"id":"2492179098","title":"Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2492179098","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492179098?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:35","pubTimestamp":1734618900,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. (Nasdaq:IMMX)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999975/0/en/Immix-Biopharma-Announces-Positive-U-S-Clinical-Data-From-First-Four-Patients-in-NEXICART-2-U-S-Trial-of-sterically-optimized-CAR-T-NXC-201-in-relapsed-refractory-Light-Chain-AL-Am.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4104","IE00B7SZL793.SGD","BK4006","CR","CRS","IE0034390439.USD","BK4161","NXC","IE00B19Z6F94.USD","BK4022","BK4572","IE0031619046.USD","CAR","IE00B19Z4B17.USD","AL","LU2065731478.USD","BK4183","IE00B66KJ199.SGD","BK4230"],"gpt_icon":0},{"id":"2492183278","title":"This AI IPO May Look Odd, But There's Beauty In Its Breakout","url":"https://stock-news.laohu8.com/highlight/detail?id=2492183278","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492183278?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:05","pubTimestamp":1734527119,"startTime":"0","endTime":"0","summary":"Fueled by AI, Oddity Tech earns a spot on the IBD Breakout Stocks Index alongside Broadcom, Salesforce and ServiceNow.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2024/12/Stock-chamelonpinkbeauty-genAI-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/12/Stock-chamelonpinkbeauty-genAI-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/research/breakout-stocks-technical-analysis/oddity-odd-stock-artificial-intelligence-ai-ipo-leader/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4588","LU1868836757.USD","ODD","LU0203345920.USD","LU1974910355.USD","LU2458330169.SGD","LU2236285917.USD","CRDO","LU0096364046.USD","LU0011850046.USD","LU0127658192.USD","IE00BMPRXR70.SGD","LU1923622614.USD","LU0795875169.SGD","LU0345770993.USD","LU2505996509.AUD","SG9999015945.SGD","LU0943347566.SGD","CRM","LU1935042488.USD","BK4532","LU1267930730.SGD","LU2237443978.SGD","BK4548","IE00BJTD4V19.USD","LU2347655156.SGD","LU2505996681.GBP","IE00BQXX3F31.USD","LU0965509010.AUD","LU1923623000.USD","AVGO","IE00BKVL7J92.USD","LU0861579265.USD","SG9999002232.USD","CRM.AU","LU1992135399.USD","LU0417517546.SGD","IE00BYV24P56.USD","IE00B1XK9C88.USD","LU0082616367.USD","IE00BMPRXN33.USD","LU0719512351.SGD","LU1934455277.USD","LU0642271901.SGD","IE00BWXC8680.SGD","LU1988902786.USD","LU1868837136.USD","LU0056508442.USD","BOUT","NOW"],"gpt_icon":1},{"id":"2492838181","title":"Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2492838181","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492838181?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526800,"startTime":"0","endTime":"0","summary":"Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/18/2998989/0/en/Praxis-Precision-Medicines-Announces-Rare-Pediatric-Disease-Designation-Granted-for-Relutrigine-in-Dravet-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4200","MDCO","BK4135","ODD","BK4139","BK4183","WRD","BK4561","PRAX","CNS","ASO","PHH"],"gpt_icon":0},{"id":"2492899789","title":"2 Megacaps and 2 Smaller Internet Stocks that Could Outperform in 2025 -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2492899789","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492899789?lang=en_us&edition=fundamental","pubTime":"2024-12-18 04:17","pubTimestamp":1734466620,"startTime":"0","endTime":"0","summary":"Many tech stocks had a blowout year, but some are still underperforming the broader market. This Truist analyst has picked several internet stocks that have been through either booms or busts that he believes will shine in 2025.Youssef Squali wrote in a research note on Tuesday that he has confidence the positive tailwinds that have helped push some tech stocks higher in 2024, including excitement over artificial intelligence and the strength in e-commerce, will continue in the new year. He's also optimistic about the opportunities awaiting several 2024 underperformers in the months to come.These are four internet stocks Squali named as his 2025 favorites.\"User engagement is also coupled with improving monetization from Reels where the company has been driving more personalization and ad load,\" Squali said. Reels is Meta's video sharing segment that directly competes with Alphabet's YouTube Shorts and TikTok. The looming ban of TikTok, which has 170 million monthly U.S. users, could al","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPR","ODD","AMZN","META"],"gpt_icon":1},{"id":"2492950248","title":"FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera","url":"https://stock-news.laohu8.com/highlight/detail?id=2492950248","media":"ACCESSWIRE","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492950248?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:30","pubTimestamp":1734442200,"startTime":"0","endTime":"0","summary":"World Health Organization  has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide. Crofelemer previously granted orphan-drug designation by the FDA and the European Medicines Agency  for both short bowel syndrome and microvillus inclusion disease. SAN FRANCISCO, CA / ACCESSWIRE / December 17, 2024 / Jaguar Health  family company Napo Pharmaceuticals  today announced that the U.S. Food and Drug Administration  has granted orphan-drug designation  to crofelemer, the company's novel plant-based prescription drug, for treatment of diarrhea in cholera.Additionally, Jaguar intends to pursue orphan-drug designation and a Tropical Disease Priority Review Voucher for the indication of treatment of diarrhea in cholera with a proprietary second-generation anti-secretory agent, NP-300, which, like crofelemer, is sustainably derived from t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/q5.go9g5djaUPSAziewZdg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/03d985faeafe92d1dfe136f95351426f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/q5.go9g5djaUPSAziewZdg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/03d985faeafe92d1dfe136f95351426f"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-orphan-drug-designation-133000989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","JAGX","BK4183","ODD"],"gpt_icon":0},{"id":"2491773692","title":"Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2491773692","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491773692?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:48","pubTimestamp":1734360480,"startTime":"0","endTime":"0","summary":"Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997631/0/en/Journal-of-Clinical-Oncology-Publishes-NXC-201-Positive-Clinical-Results-in-relapsed-refractory-AL-Amyloidosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","AL","IE00B19Z6F94.USD","CRS","IE0034390439.USD","BK4572","BK4230","LU2065731478.USD","BK4006","BK4183","NXC","IE0031619046.USD","CAR","IE00B7SZL793.SGD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","CR","BK4161","BK4104","ODD"],"gpt_icon":0},{"id":"2491669462","title":"MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2491669462","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491669462?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:37","pubTimestamp":1734356220,"startTime":"0","endTime":"0","summary":"CHICAGO, December 16, 2024----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the treatment of pediatric-type diffuse high-grade gliomas  as a drug for a \"rare pediatric disease.\". \"THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including pediatric high-grade glioma, which is among the most treatment-resistant cancers in children. THIO is shown to activate the immune system while evading tumor immunosuppression, a novel therapeutic approach for this devastating childhood disease,\" said MAIA Chairman and Chief Executive Officer Vlad Vitoc, M.D. \"We are proud to receive the FDA’s Rare Pediatric Disease designation for THIO, which significantly bolsters our plans for continuing research in the PDHGG indication.\". Rare pediatric disease priority review vouchers  can be redeemed by drug develop","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/o8xjZukNIGQajn16aQeq6Q--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a7941b4347fd25daca568f9a4279bf12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/o8xjZukNIGQajn16aQeq6Q--~B/aD0zODA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a7941b4347fd25daca568f9a4279bf12"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-granted-fda-rare-133700877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IR","BK4139","LU0256863811.USD","BK4107","HCC","LU0053666078.USD","LU0124384867.USD","LU0256863902.USD","LU0417517546.SGD","BK4006","BK4588","MAIA","BK4183","BK4161","ODD","SG9999001440.SGD","BK4585","L","LU1978683503.SGD"],"gpt_icon":0},{"id":"2491347843","title":"ODDITY Tech Initiated at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2491347843","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491347843?lang=en_us&edition=fundamental","pubTime":"2024-12-13 18:06","pubTimestamp":1734084360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 13, 2024 05:06 ET (10:06 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2491453693","title":"Barclays Sticks to Its Hold Rating for ODDITY Tech Ltd. Class A (ODD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491453693","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491453693?lang=en_us&edition=fundamental","pubTime":"2024-12-13 16:27","pubTimestamp":1734078457,"startTime":"0","endTime":"0","summary":"Barclays analyst Lauren Lieberman maintained a Hold rating on ODDITY Tech Ltd. Class A (ODD – Research Report) today and set a price target of $42....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-hold-rating-for-oddity-tech-ltd-class-a-odd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-hold-rating-for-oddity-tech-ltd-class-a-odd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2491315836","title":"Balanced Risk/Reward Outlook for ODDITY Tech: Hold Rating Amid Growth Potential and Investment Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2491315836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491315836?lang=en_us&edition=fundamental","pubTime":"2024-12-13 13:25","pubTimestamp":1734067525,"startTime":"0","endTime":"0","summary":"Bonnie Herzog, an analyst from Goldman Sachs, has initiated a new Hold rating on ODDITY Tech Ltd. Class A (ODD). Bonnie Herzog has given his Hold r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/balanced-risk-reward-outlook-for-oddity-tech-hold-rating-amid-growth-potential-and-investment-concerns?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/balanced-risk-reward-outlook-for-oddity-tech-hold-rating-amid-growth-potential-and-investment-concerns?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2491558973","title":"ODDITY Tech Ltd. Class A (ODD) Receives a Buy from JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2491558973","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491558973?lang=en_us&edition=fundamental","pubTime":"2024-12-13 02:55","pubTimestamp":1734029739,"startTime":"0","endTime":"0","summary":"In a report released today, Andrew Boone from JMP Securities reiterated a Buy rating on ODDITY Tech Ltd. Class A (ODD – Research Report), with a pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oddity-tech-ltd-class-a-odd-receives-a-buy-from-jmp-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oddity-tech-ltd-class-a-odd-receives-a-buy-from-jmp-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4183","BK4127","JMP","ODD"],"gpt_icon":0},{"id":"2490383547","title":"ODDITY Tech Ltd. Class A (ODD) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2490383547","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490383547?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:06","pubTimestamp":1734008800,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Mark Mahaney reiterated a Buy rating on ODDITY Tech Ltd. Class A (ODD – Research Report) today and set a price target of $55.0...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/oddity-tech-ltd-class-a-odd-receives-a-rating-update-from-a-top-analyst?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/oddity-tech-ltd-class-a-odd-receives-a-rating-update-from-a-top-analyst?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2490007528","title":"Cautious Hold Rating on Oddity Amid Uncertain Growth Prospects and Technological Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2490007528","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490007528?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:46","pubTimestamp":1734007563,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Dara Mohsenian maintained a Hold rating on ODDITY Tech Ltd. Class A (ODD – Research Report) today and set a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-hold-rating-on-oddity-amid-uncertain-growth-prospects-and-technological-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-hold-rating-on-oddity-amid-uncertain-growth-prospects-and-technological-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0106261372.USD","IE00BZ1G4Q59.USD","BK4183","LU1363072403.SGD","LU0158827948.USD","BK4516","LU0098860793.USD","LU2111349929.HKD","LU1989772840.SGD","LU0158827781.USD","LU2271345857.HKD","LU2028103732.USD","LU1989772923.USD","LU1668664300.SGD","LU1162221912.USD","BK4504","BK4585","LU0314104364.USD","LU2357305700.SGD","LU1720051108.HKD","LU0267386448.USD","ODD","LU2089283258.USD","LU0106831901.USD","LU2023251221.USD","IE00BKVL7J92.USD","LU1074936037.SGD","LU0006306889.USD","LU2089284900.SGD","LU0971096721.USD","BK4127","LU0320765646.SGD","LU1548497426.USD","LU1720051017.SGD","BK4588","LU0225283273.USD","BK4534"],"gpt_icon":0},{"id":"2490802932","title":"Oddity Tech Ltd : Morgan Stanley  Raises Target Price to $50.00 From $46.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2490802932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490802932?lang=en_us&edition=fundamental","pubTime":"2024-12-12 20:11","pubTimestamp":1734005498,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nAZN2TJFPC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODD","BK4183"],"gpt_icon":0},{"id":"2490301924","title":"Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2490301924","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490301924?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:39","pubTimestamp":1733841540,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. (Nasdaq:IMMX)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994665/0/en/Immix-Biopharma-Announces-75-Complete-Response-Rate-n-16-31-5-months-Best-Response-Duration-ongoing-for-CAR-T-NXC-201-in-Relapsed-Refractory-AL-Amyloidosis-Patients-at-ASH-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","CRS","BK4104","IE00B19Z4B17.USD","AL","BK4006","BK4113","NXC","IE00B66KJ199.SGD","BK4588","ODD","BK4585","CART","CAR","IE00B7SZL793.SGD","LU2463526074.USD","IE0034390439.USD","ASH","CR","BK4572","IE00B19Z6F94.USD","BK4022","IE0031619046.USD","BK4161","BK4109","BK4183"],"gpt_icon":0},{"id":"2490984088","title":"Oddity Tech Stock Earns Relative Strength Rating Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2490984088","media":"Blockhead","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490984088?lang=en_us&edition=fundamental","pubTime":"2024-12-10 04:37","pubTimestamp":1733776620,"startTime":"0","endTime":"0","summary":"ODDITY Tech shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 76 to 81.","market":"sg","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU5-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU5-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/oddity-tech-stock-earns-relative-strength-rating-upgrade/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["FTLF","ODD","IE0034390439.USD","IPAR","RS","IE00B19Z6F94.USD","BK4183","BK4006"],"gpt_icon":0},{"id":"2490665773","title":"Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media","url":"https://stock-news.laohu8.com/highlight/detail?id=2490665773","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490665773?lang=en_us&edition=fundamental","pubTime":"2024-12-09 22:33","pubTimestamp":1733754780,"startTime":"0","endTime":"0","summary":"- Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following management’s formal remarks, there will be a question-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993841/0/en/Immix-Biopharma-to-Host-Conference-Call-for-Investors-Analysts-and-Members-of-the-Media.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B66KJ199.SGD","IE00B7SZL793.SGD","ODD","BK4006","BK4181","BK4218","BK4585","HST","IE00B19Z4B17.USD","IE0031619046.USD","ISBC","BK4183","CRS","BK4211","CAR","BK4230","BK4022"],"gpt_icon":0},{"id":"2490725814","title":"3 US Growth Companies With High Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2490725814","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490725814?lang=en_us&edition=fundamental","pubTime":"2024-12-09 19:04","pubTimestamp":1733742290,"startTime":"0","endTime":"0","summary":"As of December 2024, the United States stock market is experiencing a robust period, with the S&P 500 and Nasdaq Composite reaching record highs following positive jobs data. This optimistic economic environment highlights the importance of identifying growth companies where high insider ownership can signal strong confidence in their future potential.Top 10 Growth Companies With High Insider Ownership In The United States. Click here to see the full list of 203 stocks from our Fast Growing US Companies With High Insider Ownership screener.Oddity Tech demonstrates robust growth potential, with earnings forecasted to grow at 18.5% annually, outpacing the US market. The company recently raised its earnings guidance and reported significant profit increases, with Q3 net income reaching US$17.72 million from US$3.83 million a year ago. Additionally, Oddity's share buyback program of up to $100 million reflects confidence in its valuation, currently trading 42.5% below estimated fair value.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dpOtyGW1MzOWibOF63wGXA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/e802f13e850bddcb47ade82f6ffd147a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dpOtyGW1MzOWibOF63wGXA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/e802f13e850bddcb47ade82f6ffd147a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-us-growth-companies-high-110450110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4146","BK4588","BK4548","BK4108","LU1861558580.USD","ROKU","BK4547","LU2265009873.SGD","LU1861559042.SGD","LU1804176565.USD","TBBB","BK4150","BK4524","BK4507","ONON","SRAD","BK4532","BK4585","BK4113","ODD"],"gpt_icon":1},{"id":"2489465746","title":"Datadog, Inc. (DDOG) Hits Fresh High: Is There Still Room to Run?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489465746","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489465746?lang=en_us&edition=fundamental","pubTime":"2024-12-05 22:15","pubTimestamp":1733408106,"startTime":"0","endTime":"0","summary":"Have you been paying attention to shares of Datadog ?Shares have been on the move with the stock up 29.2% over the past month. The stock hit a new 52-week high of $166.08 in the previous session. Datadog has gained 36.7% since the start of the year compared to the 33.3% move for the Zacks Computer and Technology sector and the 40.8% return for the Zacks Internet - Software industry.The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 7, 2024, Datadog reported EPS of $0.46 versus consensus estimate of $0.39 while it beat the consensus revenue estimate by 4.15%.For the current fiscal year, Datadog is expected to post earnings of $1.76 per share on $2.66 billion in revenues. This represents a 33.33% change in EPS on a 24.9% change in revenues. For the next fiscal year, the company is expected to earn $1.94 per share on $3.19 billion in revenues. This ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datadog-inc-ddog-hits-fresh-141506620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4548","BK4588","BK4551","BK4183","BK4561","LU1548497426.USD","LU1720051017.SGD","LU2357305700.SGD","LU1720051108.HKD","ODD","LU2286300806.USD","BK4535","BK4023","BK4528","DDOG","BK4585"],"gpt_icon":0},{"id":"2489175834","title":"What on Earth is happening with Mesoblast shares today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489175834","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489175834?lang=en_us&edition=fundamental","pubTime":"2024-12-05 08:54","pubTimestamp":1733360055,"startTime":"0","endTime":"0","summary":"Investors were buying and then selling the company's shares today after the allogeneic cellular medicines developer made a major announcement. According to the release, the United States Food and Drug Administration  has granted its second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell therapy Revascor Regenerative Medicine Advanced Therapy  designation. This follows the submission of results from a randomised controlled trial in children with hypoplastic left heart syndrome . HLHS is a severe congenital heart disease in which the left side of the heart does not fully develop and effective pumping of oxygenated blood by the left ventricle to the rest of the body is reduced. Mesoblast notes that without immediate surgery after birth, the prognosis is dismal with HLHS overall being responsible for 25% to 40% of all neonatal cardiac mortality. Earlier this year, FDA granted Revascor both Rare Pediatric Disease Designation  and OrphanDrug Designatio","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/05/what-on-earth-is-happening-with-mesoblast-shares-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BLA.AU","BK4139","MESO","BK7501","BK7508","BK4183","MSB.AU","BK7067","ODD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://oddity.com","stockEarnings":[{"period":"1week","weight":-0.1151},{"period":"1month","weight":0.0856},{"period":"3month","weight":0.2299},{"period":"6month","weight":0.1098},{"period":"1year","weight":-0.0709},{"period":"ytd","weight":-0.0595}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oddity Tech Ltd. operates as a consumer tech company that builds and scales digital-first brands to disrupt beauty and wellness industries. The company serves consumers worldwide through its AI-driven online platform, deploying data science to identify consumer needs, and developing solutions in the form of beauty and wellness products. It owns IL MAKIAGE and SpoiledChild brands. The company was incorporated in 2013 and is headquartered in Tel Aviv, Israel with additional office in New York, New York.","exchange":"NASDAQ","name":"ODDITY Tech Ltd.","nameEN":"ODDITY Tech Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ODDITY Tech Ltd.,ODD,ODDITY Tech Ltd.股票,ODDITY Tech Ltd.股票老虎,ODDITY Tech Ltd.股票老虎国际,ODDITY Tech Ltd.行情,ODDITY Tech Ltd.股票行情,ODDITY Tech Ltd.股价,ODDITY Tech Ltd.股市,ODDITY Tech Ltd.股票价格,ODDITY Tech Ltd.股票交易,ODDITY Tech Ltd.股票购买,ODDITY Tech Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ODDITY Tech Ltd.(ODD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ODDITY Tech Ltd.(ODD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}